Sign Out
Henplatin should be administered under the supervision of a qualified physician with experience in the use of cancer chemotherapeutic agents. Caution should be taken especially in combination therapy with potential neurotoxicity. CNS symptoms should be monitored strictly.
Henplatin is associated with digestive system toxicity, eg, nausea, vomiting, preventive and therapeutic antivomit medicine should be used.
When blood toxicity occurs (leukocyte <2000/mm3 or blood platelet <50,000/mm3), the next cycle should be delayed until recovery.
The blood amount and classification should be finished before each period of treatment and the neurologic symptoms should be checked before and after the treatment.
Continue with Google